Mereo BioPharma (MREO) Total Debt (2017 - 2023)

Mereo BioPharma (MREO) has reported Total Debt for 7 consecutive years, with $9.8 million the latest figure, recorded in Q2 2023.

• Quarterly Total Debt fell 51.09% year-over-year to $9.8 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $9.8 million (down 51.09% YoY) and the FY2022 annual result came in at $13.0 million, down 32.94% from the prior year.
• Total Debt declined to $9.8 million in Q2 2023 per MREO's latest filing, from $13.0 million in the prior quarter.
• Over the last five years, Total Debt for MREO reached as high as $34.5 million in Q2 2020 and fell as low as $9.8 million in Q2 2023.
• A 5-year average of $21.7 million and a median of $21.3 million in 2020 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2020 — Total Debt soared 35.81% — and 2023, when it slumped 51.09%.
• Year by year, Total Debt stood at $26.4 million in 2019, then fell by 19.18% to $21.3 million in 2020, then retreated by 9.03% to $19.4 million in 2021, then plunged by 32.94% to $13.0 million in 2022, then declined by 24.44% to $9.8 million in 2023.
• According to Business Quant data, Total Debt over the past three periods registered $9.8 million, $13.0 million, and $20.1 million for Q2 2023, Q4 2022, and Q2 2022 respectively.